{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:42:22Z","timestamp":1793922142972,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The combination of the checkpoint inhibitor (CPI) pembrolizumab and platinum-based chemotherapy is effective frontline therapy for advanced non-small cell lung cancer (NSCLC) lacking targetable mutations. Indoleamine 2,3- dioxygenase 1 (IDO1), an enzyme involved in kynurenine production, inhibits immune responses. Inhibition of IDO1 may restore antitumor immunity and augment CPI activity. This trial evaluated addition of epacadostat, a potent and highly selective IDO1 inhibitor, to pembrolizumab and chemotherapy for metastatic NSCLC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>ECHO-306\/KEYNOTE-715 was a partial double-blind, randomized phase II study of adults with treatment-na\u00efve stage IV NSCLC not indicated for EGFR-, ALK-, or ROS1-directed therapy. Patients were randomized to one of three treatment arms: epacadostat-pembrolizumab-chemotherapy (E\u2009+\u2009P\u2009+\u2009C; blinded), epacadostat-pembrolizumab (E\u2009+\u2009P; open-label) or placebo-pembrolizumab-chemotherapy (PBO\u2009+\u2009P\u2009+\u2009C; blinded). Stratification was by PD-L1 tumor proportion score (&lt;\u200950% vs.\u2009\u2265\u200950%) and tumor histology (non-squamous vs. squamous). A protocol amendment closed enrollment in the open-label E\u2009+\u2009P group, excluding it from efficacy analyses. Intravenous pembrolizumab (200\u00a0mg) was administered every 21\u00a0days and epacadostat 100\u00a0mg or matching placebo (oral) twice daily (BID) for\u2009\u2264\u200935 3-week cycles. The primary objective was objective response rate (ORR) for E\u2009+\u2009P\u2009+\u2009C vs. PBO\u2009+\u2009P\u2009+\u2009C.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>178 patients were randomized to E\u2009+\u2009P\u2009+\u2009C (<jats:italic>n<\/jats:italic>\u2009=\u200991) or PBO\u2009+\u2009P\u2009+\u2009C (<jats:italic>n<\/jats:italic>\u2009=\u200987); 55 were enrolled in the E\u2009+\u2009P group. The E\u2009+\u2009P\u2009+\u2009C group had a lower confirmed ORR (26.4%; 95% CI 17.7\u201336.7) than the PBO\u2009+\u2009P\u2009+\u2009C group (44.8%; 95% CI 34.1\u201355.9), with a difference of\u2009\u2212\u200918.5% (95% CI\u2009\u2212\u200932.0 \u2013 (\u2212\u20094.3); one-sided <jats:italic>P<\/jats:italic>\u2009=\u20090.9948). The E\u2009+\u2009P\u2009+\u2009C group had a numerically higher percentage of confirmed responders with extended response\u2009\u2265\u20096\u00a0months (29.2% vs. 15.4%). Circulating kynurenine levels at C1D1 were similar to those at C2D1 in all treatment groups and were not reduced to normal levels with epacadostat 100\u00a0mg BID plus P\u2009+\u2009C. The safety profile of E\u2009+\u2009P\u2009+\u2009C was consistent with that for PBO\u2009+\u2009P\u2009+\u2009C.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Addition of epacadostat 100\u00a0mg BID to pembrolizumab and platinum-based chemotherapy was generally well tolerated but did not improve ORR in patients with treatment-na\u00efve metastatic NSCLC. Evaluating epacadostat doses that normalize circulating kynurenine in combination with CPIs may help determine the clinical potential of this combination.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NCT03322566. Registered October 26, 2017.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10427-4","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T06:03:57Z","timestamp":1721887437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0452-2987","authenticated-orcid":false,"given":"Michael","family":"Boyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Clingan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Chou","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Devaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Leopold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela C.","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Samkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delvys Rodriguez","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"10427_CR1","volume-title":"Cancer Facts & Figures 2019","author":"American Cancer Society","year":"2019","unstructured":"American Cancer Society. Cancer Facts & Figures 2023. Atlanta: American Cancer Society; 2023."},{"issue":"8","key":"10427_CR2","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/annonc\/mdu123","volume":"25","author":"B Besse","year":"2014","unstructured":"Besse B, Adjei A, Baas P, Melgaard P, Nicolson M, Paz-Ars L, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line\/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25(8):1475\u201384.","journal-title":"Ann Oncol"},{"issue":"25","key":"10427_CR3","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.7150\/jca.34677","volume":"10","author":"Y Chen","year":"2019","unstructured":"Chen Y, Zhou Y, Tang L, Peng X, Jiang H, Wang G, et al. Immune-checkpoint inhibitors as the first line treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. J Cancer. 2019;10(25):6261\u20138.","journal-title":"J Cancer"},{"issue":"22","key":"10427_CR4","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"10","key":"10427_CR5","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nri1457","volume":"4","author":"AL Mellor","year":"2004","unstructured":"Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4(10):762\u201374.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10427_CR6","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","volume":"9","author":"C Uyttenhove","year":"2003","unstructured":"Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9(10):1269\u201374.","journal-title":"Nat Med"},{"issue":"2","key":"10427_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/1078-0432.CCR-16-0150","volume":"23","author":"KA Schalper","year":"2017","unstructured":"Schalper KA, Carvajal-hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, et al. Differential expression and significance of PD-L1, IDO-1, and B7\u2013H4 in human lung cancer. Clin Cancer Res. 2017;23(2):370\u20138.","journal-title":"Clin Cancer Res"},{"key":"10427_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.lungcan.2018.12.008","volume":"128","author":"K Takada","year":"2019","unstructured":"Takada K, Kohashi K, Shimokawa M, Haro A, Osoegawa A, Tagawa T, et al. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy. Lung Cancer. 2019;128:26\u201332.","journal-title":"Lung Cancer"},{"issue":"9","key":"10427_CR9","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1097\/PAS.0000000000001099","volume":"42","author":"A Volaric","year":"2018","unstructured":"Volaric A, Gentzler R, Hall R, Mehaffey JH, Stelow EB, Bullock TN, et al. Indoleamine-2,3-dioxygenase in non-small cell lung cancer: a targetable mechanism of immune resistance frequently coexpressed with PD-L1. Am J Surg Pathol. 2018;42(9):1216\u201323.","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10427_CR10","doi-asserted-by":"publisher","first-page":"6752","DOI":"10.4049\/jimmunol.176.11.6752","volume":"176","author":"F Fallarino","year":"2006","unstructured":"Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176(11):6752\u201361.","journal-title":"J Immunol"},{"issue":"1","key":"10427_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12967-018-1595-3","volume":"16","author":"A Botticelli","year":"2018","unstructured":"Botticelli A, Cerbelli B, Lionetto L, Zizzari I, Salati M, Pisano A, et al. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J Transl Med. 2018;16(1):219.","journal-title":"J Transl Med"},{"issue":"7","key":"10427_CR12","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20130066","volume":"210","author":"RB Holmgaard","year":"2013","unstructured":"Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210(7):1389\u2013402.","journal-title":"J Exp Med"},{"issue":"11","key":"10427_CR13","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1096\/fasebj.5.11.1907934","volume":"5","author":"MW Taylor","year":"1991","unstructured":"Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5(11):2516\u201322.","journal-title":"FASEB J"},{"issue":"1","key":"10427_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","volume":"4","author":"M Toulmonde","year":"2018","unstructured":"Toulmonde M, Penel N, Adam J, Chevreau C, Blay J-Y, Le Cesne A, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 2018;4(1):93\u20137.","journal-title":"JAMA Oncol"},{"issue":"17","key":"10427_CR15","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","volume":"115","author":"X Liu","year":"2010","unstructured":"Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010;115(17):3520\u201330.","journal-title":"Blood"},{"issue":"13","key":"10427_CR16","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","volume":"23","author":"GL Beatty","year":"2017","unstructured":"Beatty GL, O\u2019Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, et al. First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies. Clin Cancer Res. 2017;23(13):3269\u201376.","journal-title":"Clin Cancer Res"},{"key":"10427_CR17","unstructured":"ClinicalTrials.gov. Study to explore the safety, tolerability and efficacy of MK-3475 in combination with INCB024360 in participants with selected cancers. Identifier NCT02178722."},{"issue":"8","key":"10427_CR18","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20(8):1083\u201397.","journal-title":"Lancet Oncol"},{"issue":"2","key":"10427_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/sim.4780040211","volume":"4","author":"O Miettinen","year":"1985","unstructured":"Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213\u201326.","journal-title":"Stat Med"},{"issue":"21","key":"10427_CR20","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040\u201351.","journal-title":"N Engl J Med"},{"key":"10427_CR21","doi-asserted-by":"crossref","unstructured":"Powderly JD, Klempner SJ, Naing A, Bendell J, Garrido-Laguna I, Catenacci DVT, et al. Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I\/II ECHO-207\/KEYNOTE-723 Study.\u00a0Oncologist. 2022;27(11):905-e848.","DOI":"10.1093\/oncolo\/oyac174"},{"key":"10427_CR22","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, Phase 3 trial. Lancet. 2019;393:1819\u201330.","journal-title":"Lancet"},{"key":"10427_CR23","doi-asserted-by":"crossref","unstructured":"Smith M, Newton R, Owens S, Gong X, Tian C, Maleski J, et al. \u2005Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies.\u00a0J Immunother Cancer. 2020;8(Suppl 3):A15-6.","DOI":"10.1136\/jitc-2020-SITC2020.0028"},{"issue":"suppl 15","key":"10427_CR24","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/JCO.2017.35.15_suppl.3003","volume":"35","author":"RP Perez","year":"2017","unstructured":"Perez RP, Reis MJ, Lewis KD, Saleh MN, Daud A, Berlin J, et al. Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I\/II results of ECHO-204. J Clin Oncol. 2017;35(suppl 15):3003.","journal-title":"J Clin Oncol"},{"issue":"11","key":"10427_CR25","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","volume":"25","author":"KH Jung","year":"2019","unstructured":"Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, et al. Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors. Clin Cancer Res. 2019;25(11):3220\u20138.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10427-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10427-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10427-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T06:06:44Z","timestamp":1721887604000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10427-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":25,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["10427"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10427-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"assertion":[{"value":"26 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Independent ethics committees, as defined by the US CFR Title 21, Part 56 or equivalent country specific regulations, reviewed and approved the protocol and any amendments. The study was approved by the ethics committees at each institution (Bellberry Limited; Chang Gung Medical Foundation Institutional Review Board; China Medical University Hospital Research Ethics Committee; CEIC Area 5 Hospital Universitario La Paz Paseo de la Castellana; Chaim Sheba Medical Center Tel Hashomer Oncology Institute; CISSS de la Monteregie-Centre-Comite d'Ethique; Comitato Etico 1, Azienda Ospedaliera Universitaria-Policlinico Vittorio Emanuele; Comitato Etico Brianza; Comitato etico centrale-fondazione IRCCS-istituto nazionale dei tumori; Comitato etico-istituto europeo di oncologia; Contrada Amoretta Biomedica Azienda Ospedaliera S.G. Moscati Citta Ospedaliera pal. Uffici; Copernicus Group Independent Review Board; EC of Central Clinical Hospital with polyclinic of the Presidential Administration of the RF; Ege Uni. Tip Fakultesi Arastirma Etik Kurulu; Egeszsegugyi Tudomanyos Tanacs; LEC of Leningrad Regional Clinical Hospital; LEC of Tatarstan Republican Clinical Oncology Dispensary; Meir Medical Center Oncology Institute; National Cheng Kung University Hospital; National Taiwan University Hospital; Oaxaca Site Management Organization S.C.; Rabin Medical Center Helsinki Committee; Rambam Medical Center IRB\/IEC; SBI of Stavropol region Pyatigorskiy Oncologic dispensary; Schulman Associates IRB; Soroka Medical Center EC; St Vincents Hospital Research Office; St Vincent's Hospital Sydney Human Research Ethics Committee; Tomsk Scientific Research Institute of Oncology; UBC BCCA Research Ethics Board; Udmurtia Republic Regional Clinical Oncology Dispensary; University of Michigan Medical School Institutional Review Board; US Oncology, Inc. IRB; Western Institutional Review Board; Yorkshire and the Humber Sheffield Research Ethics Committee). All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MB reports institutional research funding from Amgen, AstraZeneca, BeiGene, Ltd., Boehringer Ingelheim, Bristol-Myers Squibb, Genentech\/Roche, Merck Sharpe & Dohme, and Pfizer; and advisory board participation for AstraZeneca, Bristol-Myers Squibb, Merck Sharpe & Dohme, and Roche. RH reports advisory board participation for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche and Seagen; and speaker honoraria from Merck Sharp & Dohme, Novartis and Roche. DU reports honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme (Israel), Roche, and Takeda; consultancy for Merck Sharp & Dohme (Israel), Roche, and Takeda; and other (travel) for AstraZeneca and Takeda. PC and W\u2013CS have nothing to disclose. CD reports advisory committee participation for Bristol-Myers Squibb and Merck. SG reports personal fees from Blueprint, Roche\/Genentech, AstraZeneca, Janssen, Bristol Myers-Squibb, Pfizer, Eli Lilly, Novartis, and Daichii; grants and personal fees from Merck; and a role on the IDMC of a phase III trial sponsored by AstraZeneca. MG reports honoraria from AstraZeneca\/MedImmune, Bristol-Myers Squibb, GlaxoSmithKline, MSD Oncology, Roche, and Takeda; consulting or advisory roles with AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Celgene, Daichii Sankyo, GlaxoSmithKline, Incyte, Inivata, Janssen, Lilly, MSD, Novartis, Pfizer, Regeneron, Roche, Sanofi, Seattle Genetics, Takeda, and Tiziana Life Sciences; Speakers\u2019 Bureau participation with AstraZeneca, Bristol-Myers Squibb, Celgene, Incyte, Lilly, MSD Oncology, Otsuka, Roche, and Takeda; and research funding from Amgen (Inst), AstraZeneca (Inst), AstraZeneca\/MedImmune (Inst), Blueprint Medicines (Inst), Bristol-Myers Squibb (Inst), Exelixis (Inst), GlaxoSmithKline (Inst), Incyte (Inst), Ipsen (Inst), Janssen (Inst), Lilly (Inst), MedImmune (Inst), Merck (Inst), MSD (Inst), Novartis (Inst), Pfizer (Inst), Roche\/Genentech (Inst), Sanofi (Inst), Spectrum Pharmaceuticals (Inst), and Takeda (Inst); and travel\/accommodation\/expenses from AstraZeneca, Pfizer, and Roche. LL, MCM, and JD are salaried employees of and own stock in Incyte Corporation. AS and YL are salaried employees of Merck & Co., Inc., Rahway, NJ, USA and own stock in the Company. DRA reports personal fees\/honoraria for consultancy and lectures from Roche, AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Eli Lilly, Pfizer, and Novartis; travel expenses from Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, and Novartis; and grant support for institutional studies from Bristol-Myers Squibb.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1250"}}